149 completed, 50 recruiting, 48 active not recruiting, 36 terminated. 348 Phase 3, 34 Phase 2.
Follow Urologic Neoplasms: new trials by email Literature Review of Urologic Neoplasms trials Research Report on Urologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Not yet recruiting | Relmada Therapeutics, Inc. | 393 | 2027-02-01 | 2026-09-02 |
| Effectiveness of Medical and Environmental Interventions to Reduce Cystoscopy Discomfort (CystoDiscomfort) Headphones, Dwell time 5-10 minutes, Dwell Time more than 10 minutes - Bladder (Urothelial, Transitional Cell) Cancer, Hematuria | Phase 3 | Not yet recruiting | Florian Schroeck | 1740 | 2026-11-01 | 2026-09-01 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055) Sac-TMT, Pembrolizumab and Berahyaluronidase alfa, Cisplatin - Bladder Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 400 | 2026-10-20 | 2026-09-21 |
| A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer Alpha1H, Transurethral Resection of Bladder Tumor (TURBT), Intravesical Chemotherapy - Urinary Bladder Neoplasms, Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 3 | Recruiting | Hamlet Pharma AB | 194 | 2026-09-17 | 2026-09-21 |
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy ureteral stents, no ureteral stent - Bladder Cancer Requiring Cystectomy, Ureteral Stents | Phase 3 | Withdrawn | Brigham and Women's Hospital | 2026-09-01 | 2026-08-13 | |
| Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone - Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect | Phase 3 | Active not recruiting | Regina Elena Cancer Institute | 236 | 2026-08-13 | 2026-08-17 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer Disitamab Vedotin (RC48), Toripalimab, Transurethral Resection of Bladder Tumor - Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | 114 | 2026-08-01 | 2026-08-10 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC Dato-DXd, Rilvegostomig, Durvalumab - High-risk Muscle Invasive Urothelial Carcinoma | Phase 3 | Recruiting | AstraZeneca | 915 | 2026-07-16 | 2026-07-22 |
| A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC SHR-1501 for Injection, BCG for Injection, Epirubicin Hydrochloride for Injection - NMIBC | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 236 | 2026-07-13 | 2026-07-20 |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC Disitamab Vedotin (RC48), Gemcitabine + Cisplatin（GC）+Toripalimab, Toripalimab (JS001 ) - Urinary Bladder Neoplasms | Phase 2 / Phase 3 | Not yet recruiting | West China Hospital | 240 | 2026-06-20 | 2026-05-27 |
| 1 Year Recurrence After Modified en Bloc Resection (ERBT) vs Transurethral Resection (TURBT) for Large Bladder Tumors En Bloc Resection of Bladder Tumor, Trans Urethral Resection of Bladder Tumor - NMIBC, TCC | Phase 3 | Recruiting | dmitry enikeev | 136 | 2026-06-08 | 2026-10-27 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer TARA-002, Investigator's Choice of Intravesical Chemotherapy - Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma | Phase 3 | Recruiting | Protara Therapeutics | 284 | 2026-05-29 | 2026-10-06 |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-15 | 2026-05-19 | |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy - Urothelial Cancer, Urinary Bladder Neoplasms | Phase 3 | Recruiting | Astellas Pharma Global Development, Inc. | 390 | 2026-05-11 | 2026-10-28 |
| Lu-177 PSMA Treatment in Cell Renal Carcinoma Lu-177 PSMA-617 - Metastatic Renal Cancer | Phase 3 | Not yet recruiting | Ankara University | 20 | 2026-05-01 | 2026-02-27 |
Showing 20 of 348. Sign in to see all of them.
Urinary Bladder Neoplasms (165) · Carcinoma, Renal Cell (122) · Kidney Neoplasms (55) · Non-Muscle Invasive Bladder Neoplasms (51) · Neoplasms (39) · Carcinoma, Transitional Cell (29) · Wilms Tumor (19) · Recurrence (18) · Neoplasm Metastasis (15) · Breast Neoplasms (12) · Prostatic Neoplasms (12) · Testicular Neoplasms (10) · Burkitt Lymphoma (9) · Neuroblastoma (9)
Female Urogenital Diseases and Pregnancy Complications (348) · Female Urogenital Diseases (347) · Male Urogenital Diseases (347) · Urogenital Diseases (347) · Urologic Diseases (343) · Urogenital Neoplasms (342) · Neoplasms by Site (341) · Neoplasms (309) · Neoplasms by Histologic Type (219) · Neoplasms, Glandular and Epithelial (208) · Carcinoma (199) · Urinary Bladder Diseases (185) · Kidney Diseases (153) · Adenocarcinoma (125)
Gemcitabine (43) · Cisplatin (30) · Mitomycin (27) · pembrolizumab (25) · Sunitinib (21) · Nivolumab (19) · BCG Vaccine (15) · Magnetic Resonance Spectroscopy (15) · Doxorubicin (14) · Sorafenib (14) · Radiotherapy (13) · cabozantinib (13) · Carboplatin (12) · Interferon-alpha (12) · atezolizumab (11)
Merck Sharp & Dohme LLC (16) · National Cancer Institute (NCI) (14) · European Organisation for Research and Treatment of Cancer - EORTC (12) · Bristol-Myers Squibb (11) · Pfizer (10) · Hoffmann-La Roche (9) · AstraZeneca (8) · Alliance for Clinical Trials in Oncology (7) · Memorial Sloan Kettering Cancer Center (7) · SWOG Cancer Research Network (7) · Children's Oncology Group (6) · Spectrum Pharmaceuticals, Inc (6) · Janssen Research & Development, LLC (5) · Novartis Pharmaceuticals (5) · Photocure (5)
United States (186) · Canada (102) · United Kingdom (96) · Italy (94) · France (87) · Spain (83) · Germany (79) · Australia (75) · Poland (71) · Netherlands (65) · South Korea (63) · Belgium (57) · China (56) · Japan (55) · Russia (55)
Savino M Di Stasi, MD, PhD (3) · Shanta Chawla, MD (3) · Bruce J. Roth, MD (2) · Daniel M. Green, MD (2) · David P. Wood, MD (2) · Elizabeth A Mullen (2) · Eugene Pietzak, MD (2) · Hein van Poppel, MD, PhD (2)
PMID 37146227, PMID 27238653, PMID 28410911, PMID 33526329, PMID 37526095, PMID 25577718, PMID 29562804, PMID 33058158, PMID 33947608, PMID 35304832, PMID 35383907, PMID 11001674, PMID 16389183, PMID 23850254, PMID 24338498, PMID 26454620, PMID 26457466, PMID 26685869, PMID 26702763, PMID 27939400, PMID 31449468, PMID 31992108, PMID 33539743, PMID 34008425, PMID 34125951, PMID 37933882, PMID 10463285, PMID 10470696, PMID 11157016, PMID 11844814, PMID 12810695, PMID 12944571, PMID 15073851, PMID 15102658, PMID 15175957, PMID 15273542, PMID 15459300, PMID 15542800, PMID 15654272, PMID 15814643, PMID 15868587, PMID 15961764, PMID 1607913, PMID 16129848, PMID 16172460, PMID 16330205, PMID 16410127, PMID 16518661, PMID 16547940, PMID 16710034
2023 (14), 2016 (9), 2018 (8), 2017 (6), U10CA180820 (6), 2014 (5), U10CA180821 (5), U10CA032102 (4), 2008 (3), 2019 (3), U10CA031946 (3), U10CA098543 (3), U10CA180868 (3), U10CA180886 (3), U10CA180888 (3)